TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.600
-0.090 (-5.33%)
Jun 11, 2025, 4:00 PM - Market closed
TScan Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 154.11 | 178.69 | 133.36 | 120.03 | 161.41 | 34.79 | Upgrade
|
| Short-Term Investments | 97.58 | 111.42 | 58.69 | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 251.69 | 290.11 | 192.04 | 120.03 | 161.41 | 34.79 | Upgrade
|
| Cash Growth | 54.62% | 51.06% | 60.00% | -25.64% | 363.93% | -16.70% | Upgrade
|
| Prepaid Expenses | 3.15 | 2.61 | 2.19 | 4.1 | 4.25 | 1.65 | Upgrade
|
| Total Current Assets | 254.84 | 292.72 | 194.24 | 124.13 | 165.65 | 36.45 | Upgrade
|
| Property, Plant & Equipment | 71.09 | 71.6 | 71.23 | 69.2 | 17.26 | 12.53 | Upgrade
|
| Other Long-Term Assets | 6.79 | 6.8 | 6.68 | 5.76 | 5.2 | 0.76 | Upgrade
|
| Total Assets | 332.71 | 371.12 | 272.15 | 199.09 | 188.11 | 49.74 | Upgrade
|
| Accounts Payable | 4.97 | 4.28 | 2.37 | 2.91 | 1.77 | 2.91 | Upgrade
|
| Accrued Expenses | 9.41 | 15.33 | 10.29 | 6.41 | 5.51 | 2.36 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 3.35 | - | - | - | Upgrade
|
| Current Portion of Leases | 4.97 | 4.57 | 3.25 | 3.68 | 1.65 | 1.42 | Upgrade
|
| Current Unearned Revenue | 10.27 | 11.7 | 10.14 | 3.87 | 11.41 | 10.63 | Upgrade
|
| Other Current Liabilities | 0.2 | 0.08 | 0.43 | 0.43 | 1.01 | 0.13 | Upgrade
|
| Total Current Liabilities | 29.82 | 35.96 | 29.82 | 17.31 | 21.34 | 17.45 | Upgrade
|
| Long-Term Debt | 32.18 | 32.07 | 26.7 | 29.29 | - | - | Upgrade
|
| Long-Term Leases | 59.88 | 60.74 | 59.14 | 53.01 | 4.39 | 6.02 | Upgrade
|
| Long-Term Unearned Revenue | 0.5 | 1.25 | 5.62 | - | 1.5 | 8.82 | Upgrade
|
| Other Long-Term Liabilities | 0.12 | 0.14 | - | 0.05 | 0.1 | 0.24 | Upgrade
|
| Total Liabilities | 122.51 | 130.15 | 121.28 | 99.66 | 27.33 | 32.52 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 619.42 | 616.01 | 398.46 | 257.81 | 252.93 | 1.07 | Upgrade
|
| Retained Earnings | -409.22 | -375.1 | -247.6 | -158.38 | -92.16 | -43.53 | Upgrade
|
| Comprehensive Income & Other | -0 | 0.05 | - | - | - | - | Upgrade
|
| Total Common Equity | 210.2 | 240.97 | 150.87 | 99.43 | 160.78 | -42.46 | Upgrade
|
| Shareholders' Equity | 210.2 | 240.97 | 150.87 | 99.43 | 160.78 | 17.22 | Upgrade
|
| Total Liabilities & Equity | 332.71 | 371.12 | 272.15 | 199.09 | 188.11 | 49.74 | Upgrade
|
| Total Debt | 97.04 | 97.38 | 92.43 | 85.98 | 6.04 | 7.43 | Upgrade
|
| Net Cash (Debt) | 154.65 | 192.73 | 99.61 | 34.04 | 155.36 | 27.36 | Upgrade
|
| Net Cash Growth | 117.76% | 93.48% | 192.60% | -78.09% | 467.91% | -25.82% | Upgrade
|
| Net Cash Per Share | 2.73 | 3.41 | 2.08 | 1.42 | 13.32 | 29.87 | Upgrade
|
| Filing Date Shares Outstanding | 56.59 | 56.59 | 47.88 | 24.23 | 23.86 | 1.14 | Upgrade
|
| Total Common Shares Outstanding | 56.59 | 56.59 | 47.83 | 24.23 | 23.91 | 1.14 | Upgrade
|
| Working Capital | 225.02 | 256.77 | 164.42 | 106.82 | 144.31 | 19 | Upgrade
|
| Book Value Per Share | 3.71 | 4.26 | 3.15 | 4.10 | 6.72 | -37.38 | Upgrade
|
| Tangible Book Value | 210.2 | 240.97 | 150.87 | 99.43 | 160.78 | -42.46 | Upgrade
|
| Tangible Book Value Per Share | 3.71 | 4.26 | 3.15 | 4.10 | 6.72 | -37.38 | Upgrade
|
| Machinery | - | 22.59 | 18.63 | 16.87 | 12.15 | 6.14 | Upgrade
|
| Construction In Progress | - | 0.1 | 0.55 | 0.01 | 1.26 | 0.78 | Upgrade
|
| Leasehold Improvements | - | 3.26 | 3.16 | 3.45 | 3.43 | 0.49 | Upgrade
|
Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.